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Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for
chemokines (DARC)
Tracey C. Dawson, Alex B. Lentsch, Zixuan Wang, John E. Cowhig, Antal Rot, Nobuyo Maeda, and Stephen C. Peiper
Duffy antigen/receptor for chemokines
(DARC) is a promiscuous receptor for
chemokines that is required for Plasmo-
dium vivax infection of erythroid cells.
This receptor is expressed by subsets of
endothelial, as well as erythroid cells.
Selection for protection from malaria in-
fection resulted in an erythroid-speciﬁc
defect, suggesting that DARC may play a
critical role in endothelial biology. Mice
with targeted disruption of this gene were
generated, and the function of DARC in
inﬂammation was explored. RNA from
spleensofhomozygousmutantmicelacked
DARC transcripts, which were abundant in
wild-type(1/1)andheterozygote(1/2)mice.
DARC2/2micelackeddevelopmentalabnor-
malitiesandwerehealthyat1year.Whereas
hematologicparameterswerewithinnormal
ranges, erythrocytes from nullizygous mice
lacked CXC and CC chemokine-binding ac-
tivity. Challenge with lipopolysaccharide re-
sulted in signiﬁcantly increased inﬂamma-
toryinﬁltratesinlungandliverofnullizygous
mice. These results suggest that DARC
modulates the intensity of inﬂammatory re-
actions as a sink for chemokines. (Blood.
2000;96:1681-1684)
© 2000 by TheAmerican Society of Hematology
Introduction
The Duffy blood group was ﬁrst described as an alloantigen in a
multiply transfused hemophiliac.1 The ﬁnding that expression of
this blood group protein was signiﬁcantly under-represented in
individuals of African ancestry, particularly in regions where the
population was resistant to infection by Plasmodium vivax,2 led to
the recognition that the Duffy-negative erythroid phenotype was
protective for infection by P vivax.3
A second major advancement of insight into the physiologic
role of the Duffy blood group antigen was the discovery that it was
identical to a promiscuous receptor for chemokines expressed on
the surface of erythrocytes.4 Chemokines promote the directed
migration of speciﬁc leukocyte subsets.5The chemokine family can
be separated into branches based on the conﬁguration of the 2
amino-proximal, of 4 positionally conserved, cysteine residues. In
the CXC branch they are separated by a single residue, whereas
they are juxtaposed in the CC branch. In general, CXC and CC
chemokines promote the formation of acute and chronic inﬂamma-
tory inﬁltrates, respectively. The receptors that transduce the
signals of chemokines are members of the serpentine receptor
family, and separate subsets of receptors mediate signaling by CXC
and CC chemokines.6 The Duffy antigen was shown to be identical
to the erythroid chemokine receptor, which has the unique capacity
to bind members of both CXC and CC branches.7 In contrast to
other receptors, the binding of ligands to Duffy antigen/receptor for
chemokines (DARC) does not induce signal transduction,8 compli-
cating the interpretation of its function.
The genetic mechanism for the erythroid Duffy-negative pheno-
type9 preserved the expression of this receptor in endothelium,10
invitingspeculationthatitplaysanimportantroleinthepathophysi-
ology of inﬂammation.11 In the current studies, the physiological
role of DARC was studied in mice rendered deﬁcient of this
receptor by gene targeting. These mice showed an exaggerated
inﬂammatory response to intraperitoneal administration of bacte-
rial lipopolysaccharide (LPS), indicating that DARC may be a
regulatory sink for chemokines.
Materials and methods
Targeted disruption of the mouse DARC gene
A 9-kilobase (kb) EcoRI fragment containing the DARC locus was cloned
from an isogenic mouse genomic library. This fragment was used to
generate the targeting construct shown in Figure 1A, which contained
4.3-kb and 1.2-kb arms of homology in the 59 and 39 regions, and a neo gene
in opposite transcriptional orientation that replaced 90 base pairs (bp) of the
DARC open reading frame. Correctly targeted embryonic stem (ES) cell
lines were injected into C57BL/6 blastocysts and subsequently implanted
into CD1 host pseudopregnant females to obtain 10 chimeric pups.Three of
these chimeras were able to readily transmit the DARC mutation through
the germline when mated with C57BL/6 mice, resulting in F1 heterozy-
gotes. F1 heterozygotes were intercrossed to obtain F2 homozygous
DARC-deﬁcient mice, which served as the experimental animals (along
with the wild-type littermate controls) in these studies. All animal
experiments were approved by institutional committees and were in
compliance with National Institutes of Health guidelines.
Genotype analysis
The genotypes of all ES cells and mice were determined by Southern blot or
polymerase chain reaction (PCR) analysis. Insertion of neo introduces a
unique EcoRI site, reducing the 9-kb EcoRI fragment to 4.5 kb in the
correctly targeted allele by Southern blotting with the use of a 39 DARC
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The wild-type DARC allele was detected by ampliﬁcation of a 400-bp PCR
product, using D1 and D2 primers that ﬂank the DARC coding exon. Primer
D1 (59-GCTAGATGTCCTGACTGTCC) is a sequence that is deleted in the
correctly targeted allele. Primer D2 (59-CCAGTAGCCCAGGTTGCATA)
iscomplementarytosequencesinexon2.PrimerDneo(59-TATGGCGCGC-
CATCGATCTC-39) is complementary to a sequence within the inserted neo
gene. D2 and Dneo were used to amplify a 300-bp fragment from the
targeted DARC gene.
RT-PCR analysis
Total RNA for RT-PCR analysis was obtained from spleens of F2 mice by
using TRIzol Reagent (Gibco-BRL). Complementary DNA (cDNA) was
synthesized from RNA templates with a poly-T primer and M-MLV RT
(Gibco-BRL). DARC cDNA was ampliﬁed by PCR, using primers D2 and
D3 (59-GCCCTGAGCCTGCAGTGCCAT-39) in exon 1, resulting in a
400-bp product.
Red blood cell chemokine binding assay
Red blood cells (RBCs), obtained from F2 mice, were incubated with 0.5
nmol/L [125I]-labeled interleukin-8 (IL-8) and MCP-1 (DuPont NEN) and
saturating amounts of unlabeled ligands. The incubation was terminated by
centrifugation through an oil mixture. Erythrocyte pellets were counted in a
gamma counter.
LPS challenge
LPS (Escherichia coli, 0111:B4; Sigma Chemical, St Louis, MO) was
administered to wild-type and nullizygous mice by intraperitoneal injection
Figure 1. Targeted disruption of the mouse DARC gene. (A) mDARC targeting strategy. Top line: Endogenous DARC gene locus showing coding exon I and exon II in a 9-kb
EcoRI fragment. A 39 1-kb SpeI-EcoR1 located outside the targeting construct was used as a probe for Southern blot analysis. Primers D1 and D2 were used for PCR
identiﬁcation of the wild-type DARC gene, and primers D2 and D3 were used to detect DARC cDNAby RT-PCR analysis. Middle line:The targeting plasmid, a 1.1-kb neo gene,
was inserted to replace the BglII-XhoI fragment. This eliminates a part of the intron and 90 bp of exon II.A59 4.3-kb EcoRI-BglII fragment was used as the 59 arm of homology
a n da3 9 1.2-kb XhoI-PstI fragment containing most of the coding exon was used for the 39 homology. A TK gene was inserted for negative selection of ES cells. The
OSDUPDELvector was used to create the targeting construct. Bottom line: The correctly targeted allele. There is a unique EcoRI site introduced with the neo gene that results
in a reduction of the germline 9-kb EcoRI fragment to 4.5 kb when the DARC probe is used for Southern blot analysis.Alternatively, the correctly targeted allele can be detected
by PCR analysis by using primers D2 and Dneo2. (B) Southern blot showing correct targeting at the DARC locus. Genomic DNA prepared from the tails of F21/1,F 2 1/2, and
F2 2/2 mice were digested with EcoRI and probed with the DARC probe, detecting bands of 9.0 kb (, wild-type) and 4.5 kb (, targeted). (C) PCR gel showing correct targeting
at the DARC locus. Genomic tail DNA from F21/1,F 2 1/2, and F2 2/2 mice was analyzed by PCR analysis with the use of primers D1, D2, and Dneo, resulting in a 400-bp
wild-type product () and a 300-bp targeted product (). (D) RT-PCR analysis of DARC-deﬁcient mice. Total RNAwas isolated and cDNAwas obtained from the spleens of F2
DARC1/1, F2 DARC 1/2, and F2 DARC 2/2 mice.There was no observable difference in the expression of DARC mRNA() between 1/1 and 1/2 mice; however, we did observe
an alternate splicing product that is produced in the spleen at 800 bp. GAPDH mRNA () served as a control. There is a faint 1.4-kb band that results from a nonfunctional
message that is produced across the neo insert.This RT-PCR analysis indicates that DARC2/2 mice have no normal DARC mRNAin their spleens. (E)Absence of IL-8 binding
to DARC-deﬁcient RBCs. For a competitive binding assay, RBCs were isolated from F2 DARC1/1, 1/2, and 2/2 mice and incubated with 0.5 nmol/L of 125I-labeled IL-8 and
varying amounts of unlabeled IL-8 (0, 100, or 500 nmol/L). Each data point represents the average of duplicate samples. Similar results were obtained in 3 independent
experiments. (F) Absence of MCP-1 binding to DARC-deﬁcient RBCs. Competitive binding assays with 125I-MCP-1 were performed as described above. Similar results were
obtained in 2 independent experiments.
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Mice were killed 2 hours after injection, and tissues were sampled for
myeloperoxidase (MPO) determination12 and histopathology.
Results
Chimeras generated from correctly targeted ES cells transmitted
the mutation through the germline when mated with C57BL/6J
mice. ES cell lines and F1 heterozygotes were genotyped by
Southern blot analysis (Figure 1B). F2 mice were genotyped by
PCR analysis (Figure 1C).
The nullizygous mice exhibited normal growth, development,
fertility, and were healthy at 1 year. No signiﬁcant differences
between DARC1/1 and DARC2/2 mice were detected in their
standard hematological parameters (data not shown).
Normal DARC messenger RNA (mRNA) expression was com-
pletely abolished in the 2/2mice as measured by RT-PCR analysis from
splenic total RNA (Figure 1D), indicating the absence of DARC
expression by endothelial cells.The effect of the DARC gene disruption
on expression of the erythrocyte chemokine receptor was examined,
using [125I]-labeled IL-8 and MCP-1. The RBCs from the DARC2/2
mice showed a marked reduction in speciﬁc binding relative to the cells
from control mice (Figure 1E,F), indicating that they lack expression of
DARC on erythroid cells.
Histologic examination of tissues from animals treated with
LPS revealed a mild granulocytic inﬁltrate in lung and liver of 1/1
mice (Figure 2A,D). In contrast, nullizygous mice had intense
granulocytic inﬁltrates in lung (Figure 2B) and scattered granulo-
cytes in hepatic sinusoids, with foci of microabscess formation
(Figure 2E). Organ neutrophil accumulation was assessed indi-
rectly by measuring tissue MPO content. Lung and liver from 2/2
mice had signiﬁcantly higher MPO levels than 1/1 mice (Figure
2C,F). Mice receiving PBS injections lacked evidence of a
signiﬁcant inﬁltrate. There was no difference between 1/1 and 2/2
mice in LPS-induced leukocyte recruitment into the peritoneal
cavity (data not shown).
Discussion
The exaggerated inﬂammatory response observed in nullizygous
mice suggests that DARC may serve as a chemokine sink and that
normal expression of DARC regulates leukocyte trafﬁcking during
inﬂammation.
Note added in proof. Following the resubmission of our
manuscript, Luo et al13 reported that DARC knockout mice have
lower MPD values than wild-type controls in lung and intestine 24
hours after intraperitoneal injection of 10 mg/kg LPS. This
represents a lower dose and a longer time interval than employed in
the current study.
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Erratum
In the article by El-Daher et al entitled “Distinct localization and function of
1,4,5IP3 receptor subtypes and the 1,3,4,5IP4 receptor GAP1IP4BP in highly
puriﬁed human platelet membranes,” which appeared in the June 1, 2000,
issue of Blood (Volume 95:3412-3422), there were 2 incorrect numbers in
Table 2. The 45Ca21 uptake for row 4 should be 35 000 6 1400* and for row 5
should be 52 300 6 700. [*P , .05 compared with respective controls using
Mann-Whitney U Conﬁdence Interval and Test using the Minitab Data
Analysis Software (Coventry, UK).]
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